Journal Club E64: Retatrutide: The 28% Drug That Is Not Approved Yet

from AZense Journal Club · host Azense Medical Education

A triple GIP, GLP-1, and glucagon agonist with striking phase 2 and phase 3 signals — and a real hospitalist problem when patients obtain unapproved products outside trials.

Episode metadata supplied by the publisher feed · Published Jun 22, 2026

Embed this episode

Attribution link and audio player

Ready to play

Journal Club E64: Retatrutide: The 28% Drug That Is Not Approved Yet

0:00 7:26

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of AZense Journal Club?

This episode is 7 minutes long.

When was this AZense Journal Club episode published?

This episode was published on June 22, 2026.

Can I download this AZense Journal Club episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!